Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025)
Innate Pharma (IPHA) posted quarterly Income from Continuing Operations of 55961177.19 for Q4 2025, up 0.59% year-on-year from 55630571.63 in Q4 2024, and down 130.4% on a QoQ basis from 24288495.96 in Q2 2025.
Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported Income from Continuing Operations for 7 consecutive years, with 55961177.19 the latest figure, recorded in Q4 2025.
- Quarterly Income from Continuing Operations rose 0.59% year-over-year to 55961177.19 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 164725708.48 (down 72.05% YoY) and the FY2025 annual result came in at 55961177.19, up 0.59% from the prior year.
- Income from Continuing Operations slipped to 55961177.19 in Q4 2025 per IPHA's latest filing, from 24288495.96 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IPHA reached as high as 2651433.45 in Q2 2023 and fell as low as 56295735.75 in Q4 2024.
- A 5-year average of 30677350.56 and a median of 26991137.36 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations plunged 5669.0% — and 2022, when it surged 65.66%.
- Year by year, Income from Continuing Operations stood at 54422663.02 in 2021, then jumped by 65.66% to 18690898.9 in 2022, then surged by 53.91% to 8614313.83 in 2023, then slumped by 553.51% to 56295735.75 in 2024, then climbed by 0.59% to 55961177.19 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 55961177.19, 24288495.96, and 56295735.75 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | -55.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -55.96 Mn |
| Jun 30, 2025 | -24.29 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Jun 30, 2024 | -28.18 Mn |
| Dec 31, 2023 | -8.61 Mn |
| Jun 30, 2023 | -2.65 Mn |
| Dec 31, 2022 | -18.69 Mn |
| Dec 31, 2021 | -54.42 Mn |
| Jun 30, 2021 | -26.99 Mn |
| Dec 31, 2020 | -943,364.09 |
| Jun 30, 2020 | -11.76 Mn |
| Dec 31, 2019 | -23.62 Mn |